← Back to headlines
Revolution Medicines Prioritizes Independence After Merck's Bid
Cancer drugmaker Revolution Medicines announced that a sale is not a priority, pushing back against acquisition attempts. This statement follows an unsuccessful $32 billion bid from Merck, indicating the biotech company's intent to remain independent.
21 Jun, 04:00 — 21 Jun, 04:00
Sources
Showing 1 of 1 sources
